Previous study in neonatal rat cardiac myocytes exposed to LPS showed luteolin reduced the TNF-α levels in the medium, downregulated the TNF-α mRNA in myocytes, inhibited degradation of IκB-β and nuclear translocation of NFκB, as well as reduced NFκB DNA binding, proposing the therapeutic potential of luteolin the management of inflammation-related myocardial diseases (Lv et al., 2011). The gene discussed is TNF; the disease is myocardial disorder.